InvestorsHub Logo
Followers 16
Posts 1362
Boards Moderated 0
Alias Born 02/06/2014

Re: edcpf post# 239993

Thursday, 10/22/2015 1:46:36 PM

Thursday, October 22, 2015 1:46:36 PM

Post# of 346073
Speaking for myself everything is predicated on SUNRISE. No additional designations for the other trials. IMO



Guys, what about a designation? Recall Peregrine got FTD at about the same time as the start of SUNRISE. Now there's a lot of new information, including from SUNRISE, about bavituximab's MOA. What are the chances of getting a designation, be it FTD or something else, for any of the new trials:

1. Paclitaxel/Docetaxel + B, HER2- MBC, to be started before YE2015

2. Durvalumab + B in solid tumors, in 2016

3. Durvalumab + B in sq+non-sq NSCLC, in 2016

4. HER2- early stage BC, under review
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News